Skip to main content
Caplight Logo









OmniSpirant Therapeutics

OmniSpirant Therapeutics

Private
IrelandHealthcare & Life Scienceshttps://www.omnispirant.com/

Last Round

Seed

Jan 14, 2025

Total Funding Raised

$13.81M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

OmniSpirant Therapeutics is a biotechnology company developing a first-in-class regenerative gene therapy platform, 'OmniSomes', for RNA-based treatments targeting respiratory diseases and cancer.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Government Contracts, Services & Consulting, Revenue Share

AI Layer

Non-AI

Keywords

exosome therapygene therapydrug delivery platformregenerative medicinecystic fibrosisstem cell exosomeslung cancerinhaled drug deliverynon-viral deliveryRNA deliveryrespiratory therapyextracellular vesiclespreclinical biotechAcute Respiratory Distress SyndromeARDS

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

OmniSpirant Therapeutics Comparables

Compare OmniSpirant Therapeutics with similar companies based on industry and business-model similarity.

OmniSpirant Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
EVerMed, Inc.
82%
Xsome Biotech
80%
Evox Therapeutics
80%

OmniSpirant Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
SeedJan 14, 2025
GrantFeb 14, 2023
GrantJun 1, 2022
GrantFeb 1, 2019

OmniSpirant Therapeutics Investors

Notable investors and investment history

OmniSpirant Therapeutics investors
InvestorRounds
European CommissionGrant
Emily's EntourageGrant
Horizon EuropeGrant
Cystic Fibrosis TrustGrant

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 28, 2026

    Monthly visitors increased 32% MoM.

  • Jun 1, 2026

    Grew 30% QoQ from 10 to 13 employees.

OmniSpirant Therapeutics Filings

Explore SEC and related filing metadata, where available.

OmniSpirant Therapeutics filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about OmniSpirant Therapeutics's valuation, stock price, and market status.

Is OmniSpirant Therapeutics a public or private company?

OmniSpirant Therapeutics is a private company.

What is the current stock price of OmniSpirant Therapeutics?

OmniSpirant Therapeutics is a private company with no public stock price. No recent secondary market data is available.

How much is OmniSpirant Therapeutics worth (valuation)?

Valuation information for OmniSpirant Therapeutics is not publicly available.

Can I buy OmniSpirant Therapeutics stock?

OmniSpirant Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was OmniSpirant Therapeutics's last funding round?

OmniSpirant Therapeutics's most recent funding round was Seed on January 14, 2025.

Who are the main investors in OmniSpirant Therapeutics?

Key investors in OmniSpirant Therapeutics include European Commission, Emily's Entourage, Horizon Europe.

Will OmniSpirant Therapeutics IPO soon?

No public IPO plans have been announced for OmniSpirant Therapeutics.

How can I track OmniSpirant Therapeutics secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor OmniSpirant Therapeutics's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersIreland
Employee Range11
Year Founded2016
Last FundingJan 14, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?